12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eladur transdur-bupivacaine: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 263 patients with chronic low back pain showed that 3 Eladur patches administered every 72 hours for 12 weeks missed the primary endpoint of significantly improving mean pain intensity scores from...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >